Accelerated access to innovative medicines for patients in need

Area of Science:

• Health policy and regulation
• Pharmaceutical access and innovation
• Healthcare economics

Background:

• Stakeholders agree on the need for improved patient access to novel and innovative medicines.
• Industry's continued development of new drugs positions regulators and payers as key gatekeepers for access.
• Early-access pathways have been increasingly implemented by regulators and payers since the late 1980s/early 1990s.

Purpose of the Study:

• To describe early-access pathway approaches implemented in four economically developed regions.
• To review the success rates of these implemented early-access initiatives.
• To suggest potential new directions for optimizing medicine access.

Main Methods:

• Descriptive analysis of early-access strategies in four distinct economic regions.
• Review and assessment of the success rates associated with various early-access pathways.
• Exploratory analysis to identify and propose future directions for policy and practice.

Main Results:

• Specific early-access approaches adopted by regulators and payers in the studied regions are detailed.
• The effectiveness and success rates of these diverse initiatives have been evaluated.
• Analysis provides insights into the current landscape of medicine access pathways.

Conclusions:

• Early-access pathways are a critical mechanism for facilitating patient access to innovative medicines.
• The study highlights the varied implementation and success of these pathways across different regions.
• Recommendations are provided for future enhancements to ensure timely and equitable medicine availability.